Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675569 | 0.85 | ALOX5 (0.52) | PTGDR2KDM4EALDH1A1POLB | |
| SCHEMBL13675685 | 0.84 | MAPT (0.50) | PTGDR2KDM4EALDH1A1HPGDTRPM8 | |
| SCHEMBL28199008 | 0.77 | PTGDR2 (0.47) | L3MBTL1PTGDR2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL2097759 | 0.70 | FFAR1 (0.53) | L3MBTL1ALDH1A1HPGDTRPM8 | |
| SCHEMBL13675585 | 0.70 | PTGDR2 (0.47) | PTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL3589816 | 0.70 | RARA (0.49) | ALDH1A1HPGD | |
| SCHEMBL1566531 | 0.69 | TRPM8 (0.60) | L3MBTL1TRPM8 | |
| SCHEMBL13674669 | 0.67 | TRPM8 (0.71) | L3MBTL1KDM4EALDH1A1HPGDTRPM8 | |
| SCHEMBL5153710 | 0.66 | ALDH1A1 (0.49) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5157521 | 0.66 | MEN1 (0.47) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270456-A1 | Novel chemical compounds | HASEGAWA MASAICHI | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270456-A1 | Novel chemical compounds | HIPK3, HIPK2, HIPK1 | L3MBTL1 1100/4885PTGDR2 3859/4885KDM4E 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.